Medincell Resumes Trading on Euronext Paris

Medincell announced that trading of its shares on Euronext Paris will resume on October 9, 2026, at 2:45 pm CEST. Trading was temporarily suspended at Medincell's request earlier in the day pending the release of this announcement. The company's shares were suspended at 9:00 am CEST.

Based in Montpellier, France, Medincell is a biopharmaceutical company focused on developing long-acting injectable treatments using its BEPO® technology. The company's treatments aim to improve adherence to medical prescriptions and reduce environmental impact. Medincell recently received FDA approval for Olanzapine LAI as a monthly treatment for schizophrenia, with a planned U.S. launch in Q4 2026 under the brand WELTRUZA™. The European Marketing Authorization Application for the same treatment was accepted in May 2026.